Intravenous immunoglobulin treatment of neurological autoimmune diseases

Journal of the Neurological Sciences

Volumn 153, Issue 2, 1998, Pages 203-214

  Stangel, Martin ^a   Hartung, Hans Peter ^b,c   Marx, Peter ^a   Gold, Ralf ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

Immunomodulation; Immunotherapy; Intravenous immunoglobulins; IVIg; Neurological autoimmune diseases; Treatment

Indexed keywords

IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE TRANSMISSION; DRUG INDICATION; GUILLAIN BARRE SYNDROME; HEADACHE; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; NEUROLOGIC DISEASE; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 18744433713     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00292-X     Document Type: Article

References (167)

1. Achiron A., Margalit R., Hershkoviz R.et al. Intravenous immunoglobulin treatment of experimental T-cell mediated autoimmune disease. J. Clin. Invest. 93:1994;600-605.
2. Achiron A., Pras E., Gilad R.et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing remitting multiple sclerosis. Arch. Neurol. 49:1992;1233-1236.
3. Achiron A., Rotstein Z., Noy S., Mashiach S., Dulitzky M., Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J. Neurol. 243:1996;25-28.
4. Amato A.A., Barohn R.J., Jackson C.E., Pappert E.J., Sahnek Z., Kissel J.T. Inclusion body myositis: Treatment with intravenous immunoglobulin. Neurology. 44:1994;1516-1518.
5. Andersson U.G., Björk L., Skansen-Saphir U., Andersson J.P. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology. 79:1993;211-216.
6. Arsura E.L., Bick A., Brunner N.G., Grob D. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. Am. J. Med. Sci. 295:1988;438-443.
7. Arsura E.L., Bick A., Brunner N.G., Namba T., Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch. Int. Med. 146:1986;1365-1368.
8. Azulay J.P., Blin O., Pouget J.et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology. 44:1994;429-432.
9. Ballow M., White W., Desbonnet B.A. Modulation of in vitro synthesis of immunoglobulin and the induction of suppressor activity by therapy with intravenous immune globulin. J. Allergy Clin. Immunol. 84:1989;595-602.
10. Bain P.G., Motomura M., Newsom-Davis J.et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 47:1996;678-683.
11. Basta M., Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94:1994;1729-1735.
12. Basta M., Langlois P.F., Marques M., Frank M.M., Fries L.F. High-dose intravenous immunoglobulin modifies complement-mediated in vitro clearance. Blood. 74:1989;326-333.
13. Ben-Chetrit E., Putterman C. Transient neutropenia induced by intravenous immune globulin. New Engl. J. Med. 326:1992;270-271.
14. Berger A.R., Herskovitz S., Scelsa S. The restoration of IVIg efficacy by plasma exchange in CIDP. Neurology. 45:1995;1628-1629.
15. Besinger U.A., Fateh-Moghadam A., Knorr-Held S., Wick M., Kissel H., Albiez M. Immunomodulation in myasthenia gravis by high-dose intravenous 7-S immunoglobulins. Ann. New York Acad. Sci. 505:1987;828-831.
16. Bijsterbosch M.K., Klaus G.G.B. Crosslinking of surface immunoglobulin and Fc receptors on B lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors. J. Exp. Med. 162:1985;1825-1836.
17. Björklander J., Cunningham-Rundles C., Lundin P., Olsson R., Sönderström R., Hanson L.A. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am. J. Med. 84:1988;107-111.
18. Blasczyk R., Westhoff U., Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 341:1993;789-790.
19. Bleck T.P. IVIg for GBS: Potential problems in the alphabet soup. Neurology. 43:1993;857-858.
20. Bouche P., Moulonguet A., Ben Younes-Chennoufi A.et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J. Neurol. Neurosurg. Psychiatry. 59:1995;38-44.
21. Bril V., Ilse W.K., Pearce R., Dhanani A., Sutton D., Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 46:1996;100-103.
22. Brox A.G., Cournoyer D., Sternbach M., Spurll G. Hemolytic anemia following intravenous gammaglobulin administration. Am. J. Med. 82:1987;633-635.
23. Burckhardt J.J., Gardi A., Oxelius V.A.et al. Immunoglobulin G subclass distribution in three human intravenous immunoglobulin preparations. Vox. Sang. 57:1989;10-14.
24. Burks A.W., Sampson H.A., Buckley R.H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. New Engl. J. Med. 314:1986;560-564.
25. Cassidy J.T., Nordby G.L. Human serum immunoglobulin concentrations: Prevalence of immunoglobulin deficiencies. J. Allergy Clin. Immunol. 55:1975;35-48.
26. Castels-van Daele M., Wijndaele L., Hunninck K., Gillis P. Intravenous immune globulin and acute aseptic meningitis. New Engl. J. Med. 323:1990;614-615.
27. Castro L.H.M., Ropper A.H. Human immune globulin infusion in Guillain-Barré syndrome: Worsening during and after treatment. Neurology. 43:1993;1034-1036.
28. Charles N., Benoit P., Vial C., Bierme T., Moreau T., Bady B. Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet. 340:1992;182.
29. Chaudhry V., Corse A.M., Cornblath D.R.et al. Multifocal motor neuropathy: Response to human immune globulin. Ann. Neurol. 33:1993;237-242.
30. Cherin P., Herson S. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry. 57(Suppl.):1994;50-54.
31. Cherin P., Herson S., Wechsler B.et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am. J. Med. 91:1991;162-168.
32. Choudhary P.P., Hughes R.A.C. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglubulin. Q. J. Med. 88:1995;493-502.
33. Constantinescu C.S., Chang A.P., McCluskey L.F. Recurrent migraine and intravenous immune globulin treatment. New Engl. J. Med. 329:1993;583-584.
34. Cook D., Dalakas M., Galdi A., Biondi D., Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 40:1990;212-214.
35. Cook S.D., Troiano R., Rohowsky-Kochin C.et al. Intravenous gamma globulin in progressive MS. Acta Neurol. Scand. 86:1992;171-175.
36. Cornblath D.R., Asbury A.K., Albers J.W.et al. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology. 41:1991;617-618.
37. Cosi V., Lombardi M., Piccolo G., Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol. Scand. 84:1991;81-84.
38. Counsell C.E., McLeod M., Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology. 44:1994;1184-1185.
39. Cross A.H., Trotter J.L., Hart W.M. Caveat regarding immunoglobulin therapy in multiple sclerosis. Ann. Neurol. 33:1993;660.
40. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. New Engl. J. Med. 325:1991;1487-1498.
41. Dalakas M.C. High-dose intravenous immunoglobulin and serum viscosity: Risk of precipitating thromboembolic events. Neurology. 44:1994;223-226.
42. Dalakas M.C., Illa I., Dambrosia J.M.et al. Efficacy of high-dose intravenous immunoglobulin in the treatment of dermatomyositis: a double-blind, placebocontrolled study. New Engl. J. Med. 329:1993;1993-2000.
43. Dalakas M.C., Quarles R.H., Farrer R.G.et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann. Neurol. 40:1996;792-795.
44. Dalakas M.C., Sonies B., Dambrosia J., Sekul E., Cupler E., Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo controlled study. Neurology. 48:1997;712-716.
45. Debre M., Bonnet M.C., Fridman W.H.et al. Infusion of Fc-gamma fragments for therapy of children vvith acute immune thrombocytopenic purpura. Lancet. 342:1993;945-949.
46. Delfraissy J.F., Tchernia G., Laurian Y., Wallon C., Galanaud P., Dormont J. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br. J. Haematol. 60:1985;315-322.
47. Devathasan G., Kueh Y.K., Chong P.N. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 2:1984;809-810.
48. Drachman D.B. Myasthenia gravis. New Engl. J. Med. 330:1994;1797-1810.
49. Duhem C., Dicato M.A., Ries F. Side-effects of intravenous immune globulins. Clin. Exp. Immunol. 97:1994;79-83.
50. Dwyer J.M. Manipulating the immune system with immune globulin. New Engl. J. Med. 326:1992;107-116.
51. Dyck P.J., Litchy W.J., Kratz K.M.et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36:1994;838-845.
52. Elliot J.L., Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with immunoglobulin. Neurology. 44:1994;967-968.
53. Enders U., Toyka K.V., Hartung H.-P., Gold R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J. Neuroimmunol. 76:1997;112-116.
54. Faed J.M., Day B., Pollock M., Taylor P.K., Nukada H., Hammond-Tooke G.D. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology. 39:1989;422-425.
55. Fateh-Moghadam A., Besinger U., Geursen R.G. Ein klinisches Modell zur Regulation der humoralen Immunantwort: Infusionstherapie. Beitr. Infusionsther. Klin. Ernähr. 9:1982;69-79.
56. Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., Mamoli, B., 1997a. Randomised placebo-controlled trial of monthly intraveous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 349, 589-593.
57. Fazekas, F., Deisenhammer, F., Strasser-Fuchs, S., Nahler, G., Mamoli, B., 1997b. Treatment effects of monthly intraveous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian immunoglobulin in MS study. Multiple Sclerosis 3, 137-141.
58. Feldman E.L., Bromberg M.B., Albers J.W., Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann. Neurol. 30:1991;397-401.
59. Frank M.M., Basta M., Fries L.F. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin. Immunol. Immunopathol. 62:1992;S82-S86.
60. French cooperative group on plasma exchange in Guillain-Barré Syndrome, 1987. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann. Neurol. 22, 753-761.
61. Gabriel C.M., Gregson N.A., Redford E.J., Davies M., Smith K., Hughes R.A.C. Human immunoglobulin ameliorates rat experimental autoimmune neuritis (EAN). Brain. 20:1997;1533-1540.
62. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin. Exp. Immunol. 97:1994;49-51.
63. Gajdos P., Outin H.D., Morel E., Raphael J.C., Goulon M. High-dose intravenous gamma globulin for myasthenia gravis: An alternative to plasma exchange? Ann. New York Acad. Sci. 505:1987;842-844.
64. Gajdos P., Chevret S., Clair B., Tranchant C., Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Annals of Neurology. 41:1997;789-796.
65. Glass J.D., Cornblath D.R. Chronic inflammatory demyelinating polyneuropathy and paraproteinemic neuropathies. Curr. Opinion. Neurol. 7:1994;393-397.
66. Grosse-Wilde H., Blasczyk R., Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens. 39:1992;74-77.
67. Guillain-Barré syndrome steroid trial group, 1993. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet, 341, 586-590.
68. Hahn A.F., Bolton C.F., Zochodne D., Feasby T.E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 119:1996;1067-1077.
69. Hansen-Schmidt S., Silomon J., Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am. J. Kidney Dis. 28:1996;451-453.
70. Hartung H.-P., Pollard J.D., Harvey G.K., Toyka K.V. Immunopathogenesis and treatment of the Guillain-Barré syndrome-part II. Muscle Nerve. 18:1995;154-164.
71. Henin Y., Marechal V., Barre-Sinoussi F., Chermann J.-C., Morgenthaler J.-J. Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox. Sang. 54:1988;78-83.
72. Heyman B. The immune complex: possible ways of regulating the antibody response. Immunol. Today. 11:1990;310-313.
73. Hohlfeld, R., Toyka, K.V., 1993. Therapies. In: Oosterhuis, H.J.G.H., de Baets, M. (Eds.), Myasthenia Gravis. CRC Press, Boca Raton, pp. 235-261.
74. Imbach P., Barandun S., d'Apuzzo V.et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1:1981;1228-1231.
75. Irani D.N., Cornblath D.R., Chaudhry V., Borel C., Hanley D.F. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology. 43:1993;872-875.
76. Jacobs B.C., Schmitz P.I.M., van der Meche F.G.A. Campylobacter jejuni infection and treatment for Guillain-Barré syndrome. N. Engl. J. Med. 335:1996;208-209.
77. Jann S., Baretta S., Moggio M., Adobbati L., Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J. Neurol. Neurosurg. Psychiatry. 55:1992;60-62.
78. Jayne D.R.W., Esnault V.L.M., Lockwood C.M. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J. Autoimmun. 6:1993;207-219.
79. Jefferis R. Idiotypy and idiotypic networks: a time to redefine concepts. Clin. Exp. Immunol. 91:1993;193-195.
80. Kaji R., Shibasaki H., Kimura J. Multifocal demyelinating motor neuropathy: Cranial nerve involvement and immunoglobulin therapy. Neurology. 42:1992;506-509.
81. Kamolvarin N., Hemachudha T., Ongpipattanakul B., Phanuphak P., Viddayakorn P., Sueblinvong T. Plasma C3c changes in myathenia gravis patients receiving high-dose intravenous immunoglobulin during crisis. Acta Neurol. Scand. 80:1989;324-326.
82. Kaveri S.-V., Dietrich G., Hurez V., Kazatchkine M.D. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin. Exp. Immunol. 86:1991;192-198.
83. Kempf C., Jentsch P., Poirier B.et al. Virus inactivation during production of intravenous immunoglobulin. Transfusion. 31:1991;423-427.
84. Klaesson S., Ringden O., Markling L., Remberger M., Lundkvist I. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand. J. Immunol. 38:1993;477-484.
85. Kleyweg R.P., van der Meché F.G.A. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J. Neurol. Neurosurg. Psychiatry. 54:1991;957-960.
86. Kleyweg R.P., van der Meché F.G.A., Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology. 38:1988;1639-1641.
87. Koehler P.J., Koudstaal J. Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillain-Barré syndrome, in combination with phenytoin. J. Neurol. 243:1996;366-367.
88. Kondo N., Ozawa T., Mushiake K.et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J. Clin. Immunol. 11:1991;152-158.
89. Kyle, R.A., Dyck, P.J., 1993. Neuropathy associated with the monoclonal gammopathies. In: Dyck, P.J., Thomas, P.K., Low, P.A., Podulso, J.F. (Eds.), Peripheral Neuropathy. W.B. Saunders, Philadelphia, pp. 1275-1287.
90. Lang B.A., Laxer R.M., Murphy G., Silverman E.D., Roifman C.M. Treatment of dermatomyositis with intravenous gammaglobulin. Am. J. Med. 91:1991;169-172.
91. Leger J.M., Younes Chennoufi A.B., Chassande B., Davila G., Bouche P., Baumann N., Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J. Neurol. Neurosurg. Psychiatry. 57(Suppl 1):1994;46-49.
92. Leung D.Y., Kurt-Jones E., Newburger J.W., Cotran R.S., Burns J.C., Prober J. Endothelial cell activation of high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 2:1989;1298.
93. Leung D.Y.M., Burns J.C., Newburger J.W., Geha R.S. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J. Clin. Invest. 79:1987;468-472.
94. Lever, A.M.L., Webster, A.D.B., Brown D., Thomas, H.C., 1984. Non-A, non-B hepatitis occuring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet, 2, 1062-1064.
95. Lewis R.A., Sumner A.J., Brown M.J., Ashbury A.K. Multifocal demyelinating neuropathy with conduction block. Neurology. 32:1982;958-964.
96. Lisak R.P. Arthritis associated with circulating immune complexes following administration of intravenous immunoglobulin therapy in a patient with chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 135:1996;85-88.
97. Lotz B.P., Engel A.G., Nishino H., Stevens J.C., Litchy W.J. Inclusion body myositis. Observations in 40 patients. Brain. 112:1989;727-747.
98. Lundquist I., van Doorn P.A., Vermeulen M., Brand A. Spontaneuous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. Clin. Immunol. Immunopathol. 67:1993;192-198.
99. Malik U., Oleksowicz L., Latov N., Cardo L.J. Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen. Ann. Neurol. 39:1996;136-139.
100. Marchalonis J.J., Kaymaz H., Dedeoglu F., Schluter S.F., Yocum D.E., Edmundson A.B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor β-chain. Proc. Natl. Acad. Sci. USA. 89:1992;3325-3329.
101. Masson P.L. Elimination of infectious agents and increase of IgG catabolism as possible mode of action of IVIg. J. Autoimmun. 6:1993;683-689.
102. Moll J.W.B., Henzen-Logmans S.C., van der Meché F.G.A. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J. Neurol. Neurosurg. Psychiatry. 56:1993;112-115.
103. Morell A., Skvaril F. Struktur und biologische Eigenschaften von Immunglobulinen und gamma-Globulin-Präparaten. Schweiz. Med. Wschr. 110:1980;80-85.
104. Mouthon L., Kaveri S.V., Spalter S.H.et al. Mechanism of action of intravenous immune globulin in immune mediated diseases. Clin. Exp. Immunol. 104(Suppl. 1):1996;3-9.
105. Newburger J.W., Takahashi M., Beiser A.S.et al. A single intravenous infusion of gammaglobulin as compared with four infusions in the treatment of acute Kawasaki syndrome. New Engl. J. Med. 324:1991;1633-1639.
106. Ng K.K.P., Howard R.S., Fish D.R.et al. Management and outcome of severe Guillain-Barré syndrome. Q. J. Med. 88:1995;243-250.
107. Ng K.K.P., Howard R.S., Hirsch N.P., Miller D.H. Intravenous immunoglobulin versus plasma exchange in Guillain-Barré syndrome. Neurology. 43:1993;2729-2731.
108. NIH consensus conference, 1990. Intravenous immunoglobulin. Prevention and treatment of disease. J. Am. Med. Assoc. 264, 3189-3193.
109. Nobile-Orazio E. Multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry. 60:1996;599-604.
110. Noseworthy J.H., O'Brien P., van Engelen B.G.M., Rodriguez M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomized, double-blind, placebo-controlled clinical trial. J. Neurol. Neurosurg. Psychiatry. 57(Suppl.):1994;11-14.
111. Okitsu-Negishi S., Furusawa S., Kawa Y.et al. Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1. Immunol. Res. 13:1994;49-55.
112. Oomes, P.G., van der Meché, F.G.A., Kleyweg, R.P., Dutch Guillain-Barré study group, 1996. Liver function disturbances in Guillain-Barré syndrome: A prospective longitudinal study in 100 patients. Neurology 46, 96-100.
113. Parry G.J., Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve. 11:1988;103-107.
114. Perosa F., Rizzi R., Pulpito V., Dammacco F. Soluble CD4 antigen reactivity in intravenous immunoglubulin preparations: is it specific? Clin. Exp. Immunol. 99:1995;16-20.
115. Pestronk A., Cornblath D.R., Ilyas A.A.et al. A treatable multifocal motor neuropathy with antibodies to GMI ganglioside. Ann. Neurol. 24:1988;73-78.
116. Plasma Exchange/Sandoglobulin Guillain-Barré syndrome trial group, 1997. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349, 225-230.
117. Prick M.J.J., Verhagen W.I.M. Chronic inflammatory demyelinating polyneuropathy: Immunoglobulins or plasmapheresis? Arch. Neurol. 48:1991;1118-1119.
118. Ratko, T.A., Burnett, D.A., Foulke, G.E., Matuszewski, K.A., Sacher, R.A., University consortium expert panel, 1995. Recommendations for off-label use of intravenously administered immunoglobulin preparations. J. Am. Med. Assoc. 273, 1865-1870.
119. Rees J. Guillain-Barré syndrome: Clinical manifestations and directions for treatment. Drugs. 49:1995;912-920.
120. Rodriguez M., Lennon V.A. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol. 27:1990;12-17.
121. Ronda N., Haury M., Nobrega A., Coutinho A., Kazatchkine M.D. Selectivity of recognition of variable (V) regions of autoantibodies by intravenous immunoglobulin (IVIg). Clin. Immunol. Immunopathol. 70:1994;124-128.
122. Ronda N., Hurez V., Kazatchkine M.D. Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox. Sang. 64:1993;65-72.
123. Ropper A.H. The Guillain-Barré syndrome. New Engl. J. Med. 326:1992;1130-1136.
124. Rosen F.S. Putative mechanism of the effect of intravenous gamma-globulin. Clin. Immunol. Immunopath. 67:1993;S41-S43.
125. Ross C., Svenson M., Hansen M.B., Vejlsgaard G.L., Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 95:1995;1974-1978.
126. Rothfelder U., Neu I., Pelka R. Therapie der Multiplen Sklerose mit Immunglobulin G. Münch. Med. Wschr. 124:1982;48-54.
127. Ruiz de Souza V., Carreno M.-P., Kaveri S.V.et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur. J. Immunol. 25:1995;1267-1273.
128. Rütter G.H. Requirements for safety and quality of intravenous immunoglobulin G preparations. J. Neurol. Neurosurg. Psychiatr. 57(Suppl.):1994;2-5.
129. Schiff R.I. Transmission of viral infections through intravenous immune globulin. New Engl. J. Med. 331:1994;1649-1650.
130. Schifferli J., Leski M., Favre H., Imbach P., Nydegger U., Davies K. High dose intravenous IgG treatment and renal function. Lancet. 337:1991;457-458.
131. Sekul E.A., Culper E.J., Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann. Intern. Med. 121:1994;259-262.
132. Silbert P.L., Knezevic W.V., Bridge D.T. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 42:1992;257-258.
133. Skansen-Saphir U., Andersson J., Björk L., Andersson U. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur. J. Immunol. 24:1994;916-922.
134. Sorensen P.S. Treatment of multiple sclerosis with IVIg: potential effect and methodology of clinical trials. J. Neurol. Neurosurg. Psychiatry. 57(Suppl.):1994;62-64.
135. Soueidan S.A., Dalakas M.C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 43:1993;876-879.
136. Stangel M., Hartung H.P., Marx P., Gold R. Side effects of high-dose intraveous immunoglobulins. Clin. Neuropharmacol. 20:1997;385-393.
137. Steg R.E., Lefkowitz D.M. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology. 44:1994;1180-1181.
138. Stricker R.B., Kwiatkowska B.J., Habis J.A., Kiprov D.D. Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch. Neurol. 50:1993;837-840.
139. Svenson M., Hansen M.B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J. Clin. Invest. 92:1993;2533-2539.
140. Takei S., Arora Y.K., Walker S.M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J. Clin. Invest. 91:1993;602-607.
141. Tan E., Hajinazarian M., Bay W., Neffand J., Mendell J. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch. Neurol. 50:1993;137-139.
142. The Dutch Guillain-Barré study group, 1994. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Ann. Neurol. 35, 749-752.
143. The Guillain-Barré syndrome study group, 1985. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35, 1096-1104.
144. Thornton C.A., Ballow M. Safety of intravenous immunoglobulin. Arch. Neurol. 50:1993;135-136.
145. Thornton C.A., Griggs R.C. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann. Neurol. 35:1994;260-268.
146. Tokano Y., Umezawa Y., Okumura K. Determination of IgG subclasses of immunoglobulin preparations for intravenous injection and the problems involved. Immunol. Res. 13:1994;56-60.
147. Tovo P.A., Miniero R., Fiandino G., Saracco P., Messina M. Fc-depleted vs intact intravenous immunoglobulin in chronic ITP. J. Pediatr. 105:1984;676-677.
148. Uchiyama M., Ichikawa Y., Takaya M., Moriuchi J., Shimizu H., Arimori S. High-dose gammaglobulin therapy of generalized myasthenia gravis. Ann. New York Acad. Sci. 505:1987;868-871.
149. Uchuya M., Graus F., Vega F., Rene R., Delattre J.-Y. Intravenous immunoglobulin treatment in paraneoplastic syndromes with antineuronal autoantibodies. J. Neurol. Neurosurg. Psychiatry. 60:1996;388-392.
150. Uemura Y., Uriyu K., Hirao Y.et al. Inactivation and elimination of viruses during the fractionation of intravenous immunoglobulin preparation: Liquid heat treatment and polyethylene glycol fractionation. Vox. Sang. 56:1989;155-161.
151. Van den Berg L.H., Frannsen H., Wokke J.H.J. Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin. Neurology. 45:1995;987-988.
152. Van den Berg L.H., Kerkhoff H., Oey P.L.et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry. 59:1995;248-252.
153. van der Meché, F.G.A., Schmitz, P.I.M., Dutch Guillain-Barré study group, 1992. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl. J. Med. 326, 1123-1129.
154. van der Meché F.G.A., van Doorn P.A. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: Immune mechanism and update on current therapies. Ann. Neurol. 37:1995;S14-S31.
155. van Doorn P.A., Brand A., Strengers P.F.W., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology. 40:1990;209-212.
156. van Doorn P.A., Brand A., Vermeulen M. Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: Inhibition in vitro and in vivo by IV immunoglobulin. Neurology. 38:1988;1592-1595.
157. van Doorn P.A., Rossi F., Brand A., van Lint M., Vermeulen M., Kazatchine M.D. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 29:1990;57-64.
158. van Doorn P.A., Vermeulen M., Brand A., Mulder P.G.H., Busch H.F.M. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch. Neurol. 48:1991;217-220.
159. van Engelen B.G.M., Hommes O.R., Pinckers A., Cruysberg J.R.M., Barkhof F., Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann. Neurol. 32:1992;834-835.
160. Vassilev T., Gelin C., Kaveri S.V., Zilber M.-T., Boumsell L., Kazatchkine M.D. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins IVIg). Clin. Exp. Immunol. 92:1993;369-372.
161. Vedanarayanan V.V., Kandt R.S., Lewis D.V., DeLong G.R. Chronic inflammatory demyelinating polyradiculoneuropathy of childhood: Treatment with high-dose intravenous immunoglobulin. Neurology. 41:1991;828-830.
162. Vera-Ramirez M., Charlet M., Parry G.J. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 42:1992;1636-1637.
163. Vermeulen M., van der Meché F.G.A., Speelman J.D., Weber A., Busch H.F.M. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J. Neurol. Sci. 70:1985;317-326.
164. Vermeulen M., van Doorn P.A., Brand A., Strengers P.F.W., Jennekens F.G.I., Busch H.F.M. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind placebo controlled study. J. Neurol. Neurosurg. Psychiatry. 56:1993;36-39.
165. Voltz R., Rosen F.V., Yousry T., Beck J., Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology. 46:1996;250-251.
166. Whittam L.R., Hay R.J., Hughes R.A.C. Eczematous reactions to human immune globulin. Br. J. Dermatol. 137:1997;481-482.
167. Woodruff R.K., Gigg A.P., Firkin F.C., Smith I.L. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 2:1986;217-218.